Washington University School Of Medicine

What Washington University School Of Medicine does

Washington University School of Medicine (WashU Medicine), founded in 1874 as the medical school of Washington University in St. Louis, is a private academic medical institution headquartered at 660 S. Euclid Avenue in St. Louis, Missouri. It operates an integrated model combining patient care, biomedical research, and medical education, serving three principal constituencies: patients seeking comprehensive medical treatment (2.9+ million visits annually), medical students and trainees, and researchers conducting biomedical and clinical research. The school ranks #2 nationally in NIH research funding and runs 2,500+ clinical trials per year, with clinical operations delivered through affiliations with Barnes-Jewish Hospital, St. Louis Children's Hospital, and the NCI-designated Siteman Cancer Center. Patient care is delivered regionally through these hospital partners and through community-based programs such as the Teal Health cervical cancer screening partnership.

The institution's research enterprise spans neuroscience, oncology, genetics, diagnostics, and immunotherapy, producing a portfolio of proprietary diagnostic tests, cell therapies, AI-enabled tools, and research platforms. Core products include the PrecivityAD and PrecivityAD2 blood-based Alzheimer's diagnostic tests commercialized through spinout C2N Diagnostics (founded 2007), WU-CART-007 (soficabtagene goleucel) CAR-T cell therapy for T-cell blood cancers licensed to spinout Wugen and holding FDA Breakthrough Therapy designation, CAR-astrocyte therapy for Alzheimer's disease (patent filed), nasal nanotherapy for glioblastoma, bispecific T-cell engager (BiTE) immunotherapy for atherosclerosis developed with Amgen, and a genetically modified hookworm therapeutic delivery platform. AI capabilities include the PrecivityAD2 p-tau217 prediction model, an experimental 3D retinal imaging AI system, De-ID privacy software for research data sharing, and validation of third-party AI tools such as Owkin's BRCAura. The school's revenue model is institutional and non-commercial: it depends on federal and NIH research grants (>$100M in documented awards across 2022-2026), clinical service revenue through hospital partners, tuition and endowment income, and technology transfer via spinout equity and licensing arrangements.

WashU Medicine's competitive position rests on a talent base that includes Nobel Prize winners and nationally recognized physician-scientists (David Holtzman, Randall Bateman, Jeffrey Gordon), sustained #2 NIH funding ranking, FDA Breakthrough Therapy and approval designations on multiple assets, and access to large research cohorts including UK Biobank, NIH All of Us, and the Alzheimer's Disease Sequencing Project. The school holds LEED Gold certification for the Gary C. Werths Building at Siteman Cancer Center and operates an active technology transfer program through its Office of Technology Management. It serves as a constituent school of Washington University in St. Louis and is not independently incorporated or publicly traded.

Name

Washington University School Of Medicine

Legal name

Washington University School of Medicine

Website

https://medicine.wustl.edu

Company type

Private

Founded year

1874

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Washington University School of Medicine is a top-two NIH-funded private academic medical institution in St. Louis that integrates patient care (2.9M+ annual visits), biomedical research (2,500+ clinical trials), and medical education, with notable spinouts in Alzheimer's diagnostics and CAR-T cell therapy.

Ownership category

akta.pro rank

Product category

Academic Medical Center

NAICS

Colleges, Universities, and Professional Schools (6113), General Medical and Surgical Hospitals (6221), Medical and Diagnostic Laboratories (62151)

SIC

Services-Educational Services (8200), Services-Hospitals (8060), Services-Medical Laboratories (8071)

akta.pro primary industry

Medical Schools (MD/DO Granting) (EDAHAGAB)

akta.pro secondary industries

Health & Biomedical Research Universities (Academic Medical Center–Affiliated) (EDAHABAC), Academic Medical Centers (AMCs) & Teaching Hospitals (HLAFAAAA), Medicine & Allied Health (Clinical) (EDAGABAG)

Keywords

• Academic medical center
• Biomedical research services
• Medical education programs
• Clinical trial services
• Specialty patient care

Headquarters

HQ city

St Louis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Distribution channels4 records

Marketing channels5 records

Core offering

Washington University School of Medicine operates as an academic medical center integrating medical education, biomedical research, and specialty patient care. It delivers physician training through MD and residency programs, conducts NIH-funded basic and clinical research, and provides tertiary and quaternary patient care across affiliated hospitals. The institution also licenses proprietary diagnostics and therapies developed in-house, such as the PrecivityAD blood test and CAR-T cell therapies, to commercial partners.

Product overview

WashU Medicine operates as an academic medical center offering a portfolio of diagnostic tests, therapeutic treatments, research tools, and digital health solutions developed through its research enterprise. Key products include the PrecivityAD and PrecivityAD2 blood-based diagnostic tests for Alzheimer's disease from spinout C2N Diagnostics, the WU-CART-007 CAR-T cell therapy for T-cell blood cancers licensed to Wugen, CAR-Astrocyte therapy for Alzheimer's disease, and De-ID privacy-preserving software for research data sharing. The institution also develops AI-powered diagnostic tools including retinal imaging analysis and cancer prediction models.

Differentiator

Problem solved

Functional benefit

Products and services

• PrecivityAD2 Alzheimer's Diagnostic Test Blood-based diagnostic test measuring plasma p-tau217 levels to detect Alzheimer's disease and predict symptom onset timing within a three to four-year window. Marketed via spinout C2N Diagnostics.
• WU-CART-007 (soficabtagene goleucel) CAR-T Cell Therapy Innovative off-the-shelf CAR-T cell immunotherapy for aggressive T-cell blood cancers using CRISPR gene editing, with 91% overall response rate and 72.7% complete remission rate in early-phase trials. Licensed to Wugen.
• CAR-Astrocyte Cellular Immunotherapy Cellular immunotherapy using engineered astrocytes expressing chimeric antigen receptors to target and clear amyloid-beta plaques in Alzheimer's disease, showing 50% plaque reduction in mouse models.
• De-ID Privacy-Preserving Research Software Software that flags sensitive information in qualitative research data to facilitate privacy-preserving sharing while protecting participant confidentiality, supporting NIH data-sharing requirements.
• AI Retinal Disease Diagnosis System Experimental AI system designed to interpret 3D images of the eye's retina for faster disease diagnosis.
• MD Medical Degree Program Medical education program training future physicians, with rigorous academic curriculum and clinical rotations across affiliated hospitals.
• Residency and Specialty Training Programs Postgraduate medical training programs across multiple specialties conducted at Barnes-Jewish Hospital and St. Louis Children's Hospital.
• Specialty Patient Care Services Comprehensive medical care across routine to rare and complex conditions delivered through Barnes-Jewish Hospital, St. Louis Children's Hospital, and Siteman Cancer Center, with 2.9+ million patient visits annually.
• Clinical Trials Program More than 2,500 clinical trials offered annually across multiple disease areas, providing patients access to investigational therapies.

Quantifiable outcome

• 91% overall response rate with WU-CART-007 in aggressive T-cell cancers
• +7 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature9 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Teal HealthcoreStrategic or Co-development Partner · 28 May 2026Collaboration to launch a pilot study in Illinois and Missouri aimed at increasing cervical cancer screening participation among underserved women using at-home HPV self-collection kits at community events. The study evaluates different enrollment pathways and seeks insights into scaling community-based, patient-centered screening methods.
• C2N DiagnosticscoreStrategic or Co-development Partner · 28 May 2026C2N Diagnostics, a St. Louis startup co-founded by Dr. David Holtzman and Dr. Randall Bateman, markets the PrecivityAD blood test for Alzheimer's disease. The test measures amyloid beta and tau proteins and received FDA approval and CMS coverage.
• WugencoreOEM/ Whitelabel/ Licensing Partner · 26 March 2026WUGEN licensed WU-CART-007/soficabtagene goleucel CAR-T cell therapy developed by WashU Medicine researchers for aggressive T-cell blood cancers. The therapy received FDA Breakthrough Therapy designation. Early-phase clinical studies showed 91% overall response rate and 72.7% complete remission rate.
• LivaNova USA, Inc.coreStrategic or Co-development PartnerMulticenter clinical trial supervised by WashU Medicine demonstrated that LivaNova's implanted vagus nerve stimulation device provides sustained relief for treatment-resistant depression. RECOVER trial enrolled nearly 500 patients at 84 sites.
• AmgencoreStrategic or Co-development PartnerCollaboration with Amgen to develop immunotherapy that reduces arterial plaque in mouse models of atherosclerosis using bispecific T-cell engager (BiTE) antibody technology.
• OwkinminorStrategic or Co-development PartnerValidation of BRCAura RUO, an AI-powered tool screening for germline BRCA1/2 mutations from digitized breast cancer pathology slides, conducted at Washington University School of Medicine in St. Louis as part of international validation across France, US, and UK.
• Centre Léon Bérard (France)minorStrategic or Co-development PartnerInternational validation of BRCAura AI tool for gBRCA mutation screening from breast cancer pathology slides, conducted across independent cohorts from France, US, and UK.
• King's College London (UK)minorStrategic or Co-development PartnerInternational validation of BRCAura AI tool for gBRCA mutation screening from breast cancer pathology slides, conducted across independent cohorts from France, US, and UK.
• Alzheimer's Disease Sequencing ProjectcoreStrategic or Co-development PartnerCONGAS study integrates genetic data from over 70,000 additional genomes from the Alzheimer's Disease Sequencing Project alongside data from Puerto Rico, Dominican Republic, Costa Rica and Spain.
• Wugen (international clinical trial)coreOEM/ Whitelabel/ Licensing PartnerInternational clinical trial led by WashU researchers demonstrated WU-CART-007, developed by WashU startup Wugen, showed 91% overall response rate against aggressive T-cell cancers.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Stanford University School of Medicine: Top-tier private research medical school with comparable biomedical research output, biotech spinout ecosystem, and Silicon Valley-adjacent technology transfer activity.
• Duke University School of Medicine: Private research medical school with comparable clinical trial volume, translational research strength, and integrated academic medical center model.
• Harvard Medical School: Elite private medical school with similarly large research enterprise, extensive hospital network, and consistent top NIH funding rankings. Most direct peer for translational research and spinout activity.
• Perelman School of Medicine (University of Pennsylvania): Private research medical school with comparable NIH funding scale, hospital affiliations, and translational pipeline in gene therapy, oncology, and neuroscience.
• Yale School of Medicine: Private research medical school with similar NIH funding profile, hospital network, and strength in biomedical discovery and physician-scientist training.
• UCSF School of Medicine: Top public research medical school with comparable scale of NIH funding, biotech industry partnerships in the Bay Area, and strength in clinical trials and translational research.
• Columbia University Vagelos College of Physicians and Surgeons: Private Ivy League medical school with similar scale of NIH-funded research, hospital affiliations, and neuroscience/oncology focus areas that overlap with WashU.
• Johns Hopkins University School of Medicine: Top-ranked US private medical school with comparable NIH-funded research, hospital affiliations, and academic medical center structure. Direct competitor for NIH grants, faculty talent, and clinical reputation.
• Weill Cornell Medicine: Private research medical school in New York with comparable NIH-funded research scale, integrated hospital partnerships, and translational pipeline.

Broad incumbents

• Mayo Clinic Alix School of Medicine: Major academic medical center with extensive clinical trial infrastructure, integrated hospital operations, and translational research — broader clinical footprint than a typical medical school but directly comparable in research and education scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/WUSTLmed
• YouTubeyoutube.com/@washumedicine
• Facebookfacebook.com/WUSTLmedicine.health
• LinkedInlinkedin.com/company/washington-university-school-of-medicine
• Instagraminstagram.com/washumedicine
• TikToktiktok.com/@washumedicine

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries2 records

Funding overview

Funding rounds11 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Washington University School Of Medicine